Next Article in Journal
Comment on Xu et al. Isolation and Identification of a Novel Phlebovirus, Hedi Virus, from Sandflies Collected in China. Viruses 2021, 13, 772
Previous Article in Journal
Release of HSV-1 Cell-Free Virions: Mechanisms, Regulation, and Likely Role in Human-Human Transmission
 
 
Article

Combination of Antiretroviral Drugs Zidovudine and Efavirenz Impairs Tumor Growths in a Mouse Model of Cancer

1
Laboratory of the Swiss Hepato-Pancreato-Biliary (HPB) and Transplantation Center, Department of Surgery, University Hospital Zürich, Raemistrasse 100, CH-8091 Zürich, Switzerland
2
Moscow Institute of Physics and Technology, Dolgoprudny, 141701 Moscow, Russia
3
World-Class Research Center “Digital Biodesign and Personalized Healthcare”, Sechenov First Moscow State Medical University, 119991 Moscow, Russia
4
Omicsway Corp., Walnut, CA 91789, USA
5
Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry, 117997 Moscow, Russia
6
Institute for Pathology, University Hospital Zürich, Raemistrasse 100, CH-8091 Zürich, Switzerland
*
Author to whom correspondence should be addressed.
Academic Editor: Ester Ballana Guix
Viruses 2021, 13(12), 2396; https://doi.org/10.3390/v13122396
Received: 27 October 2021 / Revised: 18 November 2021 / Accepted: 25 November 2021 / Published: 30 November 2021
(This article belongs to the Section Human Virology and Viral Diseases)
LINE1 retrotransposons, which are thought to be the remnants of ancient integrations of retrovirus-like elements, are aberrantly (re)activated in many cancer cells. Due to LINE1-induced alterations in target gene expression and/or chromosomal rearrangements, they may be important drivers of tumorigenesis. Moreover, LINE1 encoded proteins, Open Reading Frame (ORF)1 and ORF2, may have pro-oncogenic potential through inductors of oncogenic transcription factors or inhibitors of cell cycle suppressors. The current study therefore aimed to investigate in vitro and in vivo anti-tumorigenic effects of two well-known antiretroviral drugs, zidovudine, a nucleoside analogue inhibitor of RT (NRTI), and efavirenz, a non-nucleoside RT inhibitor (NNRTI). Our data demonstrate that both drugs in clinically relevant doses significantly reduced the proliferation of murine and human cancer cell lines, as well as growth of tumors in a murine subcutaneous model. Intriguingly, we found that the combination of both zidovudine and efavirenz almost entirely blocked tumorigenesis in vivo. Because both drugs are FDA-approved agents and the combination was very well tolerated in mice, the combination therapy as presented in our paper might be an opportunity to treat colorectal tumors and metastasis to the liver in an inexpensive way. View Full-Text
Keywords: combination therapy; antiretroviral drugs; zidovudine; efavirenz; cancer treatment combination therapy; antiretroviral drugs; zidovudine; efavirenz; cancer treatment
Show Figures

Figure 1

MDPI and ACS Style

Schneider, M.A.; Buzdin, A.A.; Weber, A.; Clavien, P.-A.; Borger, P. Combination of Antiretroviral Drugs Zidovudine and Efavirenz Impairs Tumor Growths in a Mouse Model of Cancer. Viruses 2021, 13, 2396. https://doi.org/10.3390/v13122396

AMA Style

Schneider MA, Buzdin AA, Weber A, Clavien P-A, Borger P. Combination of Antiretroviral Drugs Zidovudine and Efavirenz Impairs Tumor Growths in a Mouse Model of Cancer. Viruses. 2021; 13(12):2396. https://doi.org/10.3390/v13122396

Chicago/Turabian Style

Schneider, Marcel A., Anton A. Buzdin, Achim Weber, Pierre-Alain Clavien, and Pieter Borger. 2021. "Combination of Antiretroviral Drugs Zidovudine and Efavirenz Impairs Tumor Growths in a Mouse Model of Cancer" Viruses 13, no. 12: 2396. https://doi.org/10.3390/v13122396

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop